Novo Nordisk, a leader in the obesity drug sector, revealed plans to launch over five drugs with 'multi-blockbuster' potential by 2030 and to achieve more than 150 billion Danish kroner ($23 billion) in pipeline sales by 2035. The company also projected revenue growth from 2026 to 2030 to align with industry peers.
However, despite these optimistic targets, the market reacted negatively, leading to a 7% decline in its Copenhagen-listed shares during morning trading. This decline highlights investor skepticism about Novo's ability to maintain its competitive edge in a rapidly evolving market where competition is intensifying